The most common side effect is hypoglycemia, the frequency of which depends, as with any kind of diabetes therapy, on individual factors such as eating habits, the dose of the drug, physical activity and stress.
From the immune system: very rarely - generalized hypersensitivity reactions or immunological reactions such as vasculitis can be detected; unknown - hypersensitivity reactions, such as itching, rash, urticaria.From the side of metabolism: often - hypoglycemia; unknown - hypoglycemic coma, hypoglycemia with loss of consciousness. As with other hypoglycemic agents, hypoglycemia may develop with repaglinide.In most cases, these reactions are mild and can be eliminated by taking carbohydrates. In severe reactions, medical attention may be required, in particular, intravenous dextrose (glucose). The risk of developing hypoglycemia may increase with the interaction of repaglinide with other drugs.
From the side of the organ of vision: very rarely - vision disorders. Changes in the concentration of glucose in the blood can lead to visual disturbances, especially at the initial stage of therapy with hypoglycemic drugs. However, usually these changes are transitory.
From the cardiovascular system: rarely - cardiovascular diseases. The risk of cardiovascular disease is increased in type 2 diabetes mellitus. There was an increased risk of acute coronary syndrome in patients who received repaglinide, compared with patients receiving the sulfonylurea derivative, but not compared to patients receiving metformin or acarbose. However, the causal relationship is not established.
From the digestive system: often - abdominal pain, diarrhea; very rarely - vomiting, constipation; unknown - nausea.
From the liver and bile ducts: very rarely - violations of the liver function; in very rare cases, serious violations of liver function were reported (causal relationship with repaglinide was not established), increased activity of hepatic enzymes.